Octapharma

Horizon pips Roche to rare disease reputation crown, Pfizer dips

Horizon, which ranked third among rare disease patient groups last year, climbed to first place on the listing this year and bumped Roche off the top.

Nick Paul Taylor Aug 24, 2023 8:20am

Octapharma secures FDA nod for warfarin reversal agent Balfaxar

Jul 26, 2023 3:15pm

FDA extends immunodeficiency drug's shelf life to ease shortage

Jan 6, 2021 6:20pm